Antibacterial activity and PK/PD of ceftriaxone against penicillin-resistant Streptococcus pneumoniae and β-lactamase-negative ampicillin-resistant Haemophilus influenzae isolates from patients with community-acquired pneumonia

Journal of Infection and Chemotherapy

Volumn 13, Issue 5, 2007, Pages 296-301

  Ohno, Akira ^a   Ishii, Yoshikazu ^a   Kobayashi, Intetsu ^b   Yamaguchi, Keizo ^a  

^a TOHO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b LSI MEDIENCE CORPORATION   (Japan)

Author keywords

Ceftriaxone; Community acquired pneumonia; Penicillin resistant Streptococcus pneumoniae (PRSP); Pharmacokinetics pharmacodynamics (PK PD); lactamase negative ampicillin resistant (BLNAR)

Indexed keywords

AMPICILLIN; BETA LACTAMASE; CEFOTIAM; CEFTRIAXONE; FLOMOXEF; MEROPENEM; SULPERAZON; SULTAMICILLIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIUM ISOLATE; COMMUNITY ACQUIRED PNEUMONIA; HAEMOPHILUS INFLUENZAE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PENICILLIN RESISTANCE; STREPTOCOCCUS PNEUMONIAE;

EID: 35848970092     PISSN: 1341321X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10156-007-0539-2     Document Type: Article

References (22)

1. I Beobide A Canut AR Gascon A Isla C Garcia-Rey I De La Maza 2005 Evaluation of antimicrobial treatments in children with acute otitis media in Spain: a pharmacokinetic-pharmacodynamic (PK/PD) approach J Chemother 17 628 35
2. F Sudo A Nakamura T Hoshino N Ishiwada Y Kohno 2004 Successful treatment of β-lactamase-negative ampicillin-resistant Haemophilus influenzae type b meningitis with high-dose ceftriaxone administration Kansenshogaku Zasshi 78 604 8
3. R Yogev J Guzman-Cottrill 2005 Bacterial meningitis in children: critical review of current concepts Drugs 65 1097 112
4. K Hasegawa N Chiba R Kobayashi SY Murayama S Iwata K Sunakawa K Ubukata 2004 Rapidly increasing prevalence of β-lactamase-nonproducing, ampicillin-resistant Haemophilus influenzae type b in patients with meningitis Antimicrob Agents Chemother 48 1509 14
5. K Yamaguchi A Ohno Levofloxacin Surveillance Group 2005 Investigation of the susceptibility trends in Japan to fluoroquinolones and other antimicrobial agents in a nationwide collection of clinical isolates: a longitudinal analysis from 1994 to 2002 Diagn Microbiol Infect Dis 52 135 43
6. TM File Jr 2004 Streptococcus pneumoniae and community-acquired pneumonia: a cause for concern Am J Med 117 Suppl 3A 39S 50S
7. EJ Begg ML Barclay CJ Kirkpatrick 1999 The therapeutic monitoring of antimicrobial agents Br J Clin Pharmacol 47 23 30
8. RN Brogden A Ward 1988 Ceftriaxone. A reappraisal of its antibacterial activity and pharmacokinetic properties, and an update on its therapeutic use with particular reference to once-daily administration Drugs 35 604 45
9. JH Yuk CH Nightingale R Quintiliani 1989 Clinical pharmacokinetics of ceftriaxone Clin Pharmacokinet 17 223 35
10. K Stoeckel JR Koup 1984 Pharmacokinetics of ceftriaxone in patients with renal and liver insufficiency and correlations with a physiologic nonlinear protein binding model Am J Med 77 26 32
11. JA Karlowsky ME Jones DC Mayfield C Thornsberry DF Sahm 2002 Ceftriaxone activity against Gram-positive and Gram-negative pathogens isolated in US clinical microbiology laboratories from 1996 to 2000: results from The Surveillance Network (TSN) Database-USA Int J Antimicrob Agents 19 413 26
12. DM Richards RC Heel RN Brogden TM Speight GS Avery 1984 Ceftriaxone. A review of its antibacterial activity, pharmacological properties and therapeutic use Drugs 27 469 527
13. GL Drusano FW Goldstein 1996 Relevance of the Alexander Project: pharmacodynamic considerations J Antimicrob Chemother 38 Suppl A 141 54
14. th ed ASM Washington, DC
15. Clinical and Laboratory Standards Institute. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically-seventh edition: approved standard M7-A7. Wayne, PA: CLSI; 2006
16. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility tests; 16th informational supplement M100-S16. Wayne, PA: CLSI; 2006
17. AP MacGowan R Wise 2001 Establishing MIC breakpoints and the interpretation of in vitro susceptibility tests J Antimicrob Chemother 48 Suppl 1 17 28
18. W Craig 1998 Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men Clin Infect Dis 26 1 10
19. K Matsuzaki K Shito E Watabe M Hasegawa Y Sato I Kobayashi 2005 Antibacterial activity of ceftriaxone against various clinical strains isolated in 2004 Jpn J Antibiot 58 283 89
20. AC Popick WG Crouthamel I Bekersky 1987 Plasma protein binding of ceftriaxone Xenobiotica 17 1139 45
21. M Komatsu A Nakamura M Aihara M Komatsu A Nakamura M Aihara 2003 Application of the MIC breakpoints based on pharmacokinetics and pharmacodynamic parameters in the clinical laboratory Jpn J Antibiot 56 697 704
22. GL Drusano 2003 Prevention of resistance: a goal for dose selection for antimicrobial agents Clin Infect Dis 36 Suppl 1 S42 50